BPC-157 TB-500, 20 mg by PEPTIDOLOGY

PEPTIDOLOGY BPC-157 + TB-500 20 mg is a dual-compound, lyophilized peptide blend supplied exclusively for controlled professional laboratory research. The product combines research materials identified as BPC-157 and TB-500 within one vial containing a stated total quantity of 20 mg.

Quantity clarification: The 20 mg value represents the combined total amount of both compounds. The product page does not specify how the total is divided between BPC-157 and TB-500. It must not be described as containing 20 mg of each compound or automatically assumed to provide a 10 mg + 10 mg ratio. Researchers should verify the individual component quantities using the batch-specific certificate of analysis.

The product listing states a purity of at least 99% with HPLC and mass-spectrometry verification. This is a supplier-declared analytical specification and should not be interpreted as proof of sterility, endotoxin control, clinical safety, pharmaceutical manufacturing compliance or suitability for human administration.

Scientific Context of the Research Blend

BPC-157: BPC-157 is generally described as a synthetic 15-amino-acid peptide related to a sequence called body protection compound. Published investigations have been primarily preclinical and have examined areas such as cellular responses, gastrointestinal models, inflammatory signaling, vascular processes and tissue-related experimental endpoints.

These studies do not establish approved therapeutic benefits in humans. FDA has identified limited human safety information and potential concerns involving immunogenicity, peptide aggregation, peptide-related impurities and active-ingredient characterization.

TB-500: The term TB-500 is commonly used commercially for a synthetic material related to thymosin beta-4. FDA documentation describes the evaluated TB-500 bulk substance as a seven-amino-acid fragment corresponding to the LKKTETQ region of thymosin beta-4.

The name TB-500 is not a standardized United States Adopted Name, and different salts, fragments or related active materials may be marketed using the same common name. Researchers must therefore confirm the sequence, molecular mass, salt form and analytical reference standard shown on the certificate of analysis.

Combined-Blend Research: Combining two compounds in one vial does not demonstrate synergy, improved experimental activity or clinical benefit. Each compound may have different stability, solubility, analytical response and concentration requirements. Blend-based research should include suitable controls for each component and for the combined material.

Key Research Features

Product Specifications

Certificate-of-Analysis Requirements

Because this product contains two compounds, a useful batch certificate should identify more than one general purity percentage. Researchers should look for the individual identity and quantity of BPC-157 and TB-500, the precise peptide sequences, molecular masses, salt or counter-ion forms, chromatographic purity results and matching mass-spectrometry data.

Where the material might be used in sensitive cellular or biological assays, additional quality characteristics may be relevant, including residual solvents, water content, peptide-related impurities, aggregation, bioburden and endotoxin testing. HPLC purity alone does not establish these characteristics.

Research Handling and Storage

Receiving Inspection

Qualified personnel should document the vial condition, product name, supplier, batch number, stated total quantity and storage history. Confirm that the certificate of analysis corresponds to the exact batch received.

Storage Conditions

The listing instructs storage of the sealed vial at 2–8°C away from light, with −20°C specified for long-term storage. Follow any more specific batch documentation supplied by PEPTIDOLOGY and maintain an appropriate temperature log.

Laboratory Handling

Handle only in a qualified research environment using appropriate personal protective equipment, calibrated instruments, suitable containment and an approved chemical-hygiene or biosafety protocol. Avoid inhalation, ingestion, skin exposure and cross-contamination.

Experimental Preparation

No human dosage, reconstitution, injection, compounding, stacking or self-experimentation instructions are provided or implied. Experimental preparation must be based on verified supplier documentation, validated laboratory methods and an institutionally approved protocol.

Waste Disposal

Unused material, contaminated consumables and experimental waste must be disposed of according to institutional requirements and applicable chemical or biological waste regulations. Do not discard the material into household waste or drains.

Frequently Asked Questions

Does the vial contain 20 mg of BPC-157 and 20 mg of TB-500?

No. The product page states 20 mg total across the complete two-compound blend.

Is the blend divided into 10 mg BPC-157 and 10 mg TB-500?

The product page does not provide that ratio. A 10 mg + 10 mg division must not be assumed without batch-specific documentation.

What is BPC-157?

BPC-157 is an experimental synthetic peptide consisting of 15 amino acids. Most published investigations are preclinical, and established human safety and efficacy data are lacking.

What is TB-500?

TB-500 is a common commercial name used for material related to thymosin beta-4. FDA’s recent evaluation describes the nominated TB-500 substance as the seven-amino-acid LKKTETQ fragment, but inconsistent commercial naming makes batch-level identity verification essential.

Are BPC-157 or TB-500 approved medicines?

No. Neither compound in this research blend is approved by FDA for human clinical use, and the product itself is expressly classified for laboratory research only.

Does the blend repair injuries or accelerate healing?

No therapeutic claim is established for this research product. Interest in tissue-response and repair-related pathways is based largely on experimental and preclinical research and must not be presented as proven treatment in humans.

Can the vial be injected or consumed?

No. The listing states that the product is not intended for human or veterinary consumption or administration.

Does ≥99% purity establish pharmaceutical quality?

No. A purity percentage does not establish sterility, endotoxin control, impurity characterization, clinical safety, dosing accuracy or pharmaceutical manufacturing compliance.

Are BPC-157 and TB-500 prohibited in competitive sport?

Yes. BPC-157 is prohibited under the WADA category for non-approved substances, while TB-500 is prohibited within the peptide hormones, growth factors and related substances category. Both are prohibited at all times.

Research-use notice: For controlled laboratory research only. Not a dietary supplement, medicine or cosmetic product. Not intended for human or veterinary consumption, administration, diagnosis, treatment, cure or disease prevention.